TFA Therapeutics (RAJAF) Cash & Equivalents (2020 - 2025)

TFA Therapeutics has reported Cash & Equivalents for 6 years, with the latest figure at $3199.0 in Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 91.42% year-over-year to $3199.0 in Q4 2025; TTM through Dec 2025 was $3199.0, a 91.42% decrease from a year earlier, with the FY2025 full-year figure at $3199.0, down 91.42% from the prior year.
• Cash & Equivalents was $3199.0 for Q4 2025 at TFA Therapeutics, down from $37284.0 in the prior quarter.
• The five-year high for Cash & Equivalents was $99487.0 in Q4 2021, with the low at $3199.0 in Q4 2025.
• Average Cash & Equivalents over 5 years is $31102.2, with a median of $20007.5 recorded in 2023.
• The sharpest annual moves came in 2021 and 2022: Cash & Equivalents soared 33739.12% in 2021, then tumbled 93.34% in 2022.
• Over 5 years, Cash & Equivalents stood at $99487.0 in 2021, then sank by 93.34% to $6628.0 in 2022, then surged by 248.58% to $23104.0 in 2023, then soared by 61.37% to $37284.0 in 2024, then sank by 91.42% to $3199.0 in 2025.
• The last three Cash & Equivalents figures came in at $3199.0 (Q4 2025), $37284.0 (Q4 2024), and $23104.0 (Q4 2023), per Business Quant data.